Tumor-infiltrating immune cells promoting tumor invasion and metastasis: Existing theories

Journal of Cancer

Volumn 4, Issue 1, 2013, Pages 84-95

  Man, Yan Gao ^a,b   Stojadinovic, Alexander ^c   Mason, Jeffrey ^d   Avital, Itzhak ^e   Bilchik, Anton ^f   Bruecher, Bjoern ^g   Protic, Mladjan ^h   Nissan, Aviram ⁱ   Izadjoo, Mina ^a   Zhang, Xichen ^b   Jewett, Anahid ^f  

^a Henry Jackson Foundation   (United States)

^b JILIN UNIVERSITY   (China)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Bon Secours Cancer Institute   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Theodor Billroth Academy   (Germany)

^h UNIVERSITY OF NOVI SAD   (Serbia)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Immune cell; Invasion; Metastasis; Tumor progression

Indexed keywords

ACETYLSALICYLIC ACID; GROWTH FACTOR;

CANCER CELL; CANCER PREVENTION; CANCER STEM CELL; CELL FUSION; CELL INFILTRATION; COLORECTAL CANCER; CYTOLYSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; LEUKOCYTE; LYMPHOCYTOTOXICITY; MACROPHAGE; METASTASIS; MONOCYTE; NATURAL KILLER CELL; PARACRINE SIGNALING; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; TUMOR INFILTRATING IMMUNE CELL; TUMOR INVASION; TUMOR PROMOTION;

EID: 84880751907     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5482     Document Type: Review

References (165)

1. Luebeck EG, Hazelton WD. Multistage carcinogenesis and radiation. J Radiol Prot. 2002; 22(3A):A43-9.
2. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis and the incidence of human cancer. Genes Chromosomes Cancer. 2003 Dec;38(4):302-6.
3. Laconi E, Doratiotto S, Vineis P. The microenvironments of multistage carcinogenesis. Semin Cancer Biol. 2008 Oct;18(5):322-9.
4. Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2010; 9(1-6):325-39.
5. Christofori G. New signals from the invasive front. Nature. 2006; 441(7092): 444-450.
6. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-73.
7. Jemal A, bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin. 2011; 61(2):69-90.
8. Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther. 2009; 9(12):1829-47.
9. Bonkhoff H, Wernert N, Dhom G, Remberger K. Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 1991; 418:375-81.
10. Kosir MA, Wang W, Zukowski KL, Tromp G. Degradation of basement membrane by prostate tumor heparanase. J Surg Res, 1999; 81:42-7.
11. Guelstein VI, Tehypysheva TA, Ermilova VD, Liubimov AV. Myoepithelial and besement membrane antigens in benign and malignant human breast tumors. In J Cancer 1993; 53:269-77.
12. Nerlich A. Morphology of basement membrane and associated matrix proteins in normal and pathological tissues. Veroff Pathol 1995; 145: 1-139.
13. Noffsinger A, Fenoglio-Preiser CM, Maru D, Gilinsky N. Gastrointestinal Diseases. Washington DC: American Registry of Pathology and Armed Forces Institute of Pathology. 2007; : 1-31.
14. Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 1986; 12: 294-307.
15. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-7.
16. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19:1589-92.
17. Jones JL, Glymp Walker RA. Expression of MMP-1 and MMP-9, their inhibitors, and activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189:161-8.
18. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human cancer cell invasion. Clin Cancer Res. 1995; 1: 1089-94.
19. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res. 1996; 8: 69-75.
20. Abramjuk C, Jung K, Krell HW, Juchem P, Peters R, Taymoorian K, et al. Matrix metalloproteinase inhibitor RO 28-2653 in combination with estramustine: tumor-reduced effects on hormone-sensitive prostate cancer in rats. Anticancer Drug. , 2005; 16: 855-61.
21. Harvei S, Skijorten FJ, Robsahm TE, Berner A, Tretli S. Is prostaticibtraepithelial neoplasi in the transitio/central zone a true presursor of cancer?.A long-tern retrospectivestudy in Norway. Br J Cancer. 1998; 78: 46-9.
22. Goeman L, Joniau S, Ponette D, Van der Aa F, Roskams T, Oyen R, Van Poppel H. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer. Prostate Cancer Prostatic Dis. , 2003; 6:305-10.
23. Page DL, Duppont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 1982; 49:751-58.
24. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continues local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995; 76:1197-2000.
25. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994; 11:223-35.
26. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science. 2002; 295 (5564): 2387-92.
27. Matrisian LM, Sledge GW Jr, Mohla S. Exacellular proteolysis and cancer: meeting summary and future directions. Cancer Res, 2003; 63:6105-9. 28. Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellstrom KE. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci USA. 2004; 101:10721-5.
28. Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellstrom KE. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci USA. 2004; 101:10721-5.
29. Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Anderson KM. A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA. 2005; 102: 19093-6.
30. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007; 12(4):418-25.
31. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997; 18: 267-268.
32. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 1994; 74:1275-1282.
33. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 1643-1647.
34. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother. 2010; 59: 653-661.
35. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 22: 350-366.
36. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2566.
37. Gannot G, Gannot I, Vered H, Buchner A, Keisaris Y. Increase in immune cell infiltration with progression of oral epithelium from hyperkeratiosis to dysplasia and carcinoma. Br J Cancer. 2002; 86: 1444-1448.
38. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year follow-up study. J Urol 2006; 176: 1012-1016.
39. Smith CJ, Gardner WA Jr. Inflammation-proliferation: possible relationships in the prostate. Prog Clin Biol Res 1987; 239: 317-325.
40. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989; 142(10): 3714-25.
41. Benson JL, Niederkorn JY. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber. Immunology. 1991 Sep; 74(1): 153-9.
42. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 1991 Aug 15; 51(16): 4257-65.
43. Hald J, Rasmussen N, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1995 Oct; 41(4): 243-50.
44. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med. 2000 Jun; 6(6): 465-79.
45. Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, Walker PRCutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol. 2003 Sep 1;171(5):2187-91.
46. Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S. Pecorelli SInduction of tumor-specific cytotoxicity intumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol. 2003 May; 89(2):.271-80.
47. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007 Jul 1; 13(13): 3951-9.
48. Hakim AA. A mechanism by which human breast carcinoma cells escape the host immune system. Neoplasma. 1988; 35(6): 691-705.
49. O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol. 1998 Nov; 186(3): 240-6.
50. Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999 Feb; 44(2): 156-62.
51. Nagao M, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Ko S, Tatekawa Y, Ikeda N, Kanokogi H, Urizono Y, Kobayashi T, Shibaji T, Kanamura T, Ogawa S, Nakano H. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology. 2000 Sep; 32(3): 491-500.
52. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res. 2001 Sep; 7(9): 2682-92.
53. Nakamura Y, Yamazaki K, Oizumi S, Nakashima M, Watanabe T, Dosaka-Akita H, Nishimura M.Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci. 2004 Mar; 95(3): 260-5.
54. Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009 Nov 1; 100(6): 500-4.
55. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011 Jul; 11(7): 856-61.
56. Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012 Aug 1; 1(5): 717-725.
57. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011 May 1; 236(5): 567-79.
58. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer . 2004; 4: 71-78.
59. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004. 64(19): 7022-7029.
60. Wyckoff JB, Wang Y, Lin EY, Li JF. Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007. 67(6): 2649-2656.
61. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008 Sep; 84(3):623-30.
62. Haley PJ. Species differences in the structure and function of the immune system. Toxicology. 2003; 188: 49-71.
63. Tayeh MA., Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem. 1989; 264: 19654-19658.
64. Schoedon G., Schneemann M., Hofer S., Guerrero L., Blau N., Schaffner A. Regulation of the L-arginine-dependent and tetrahydrobiopterin- dependent biosynthesis of nitric oxide in murine macrophages. Eur J Biochem. 1993; 213: 833-839.
65. Schneemann M, Schoedon G. Species differences in macrophage NO production are important. Nat Immunol. 2002; 3: 102.
66. Schneemann M, Schoeden G. Macrophage biology and immunology: man is not a mouse. J Leukoc Biol. 2007; 81: 579.
67. Mestas J., Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004; 172: 2731-2738.
68. Pfister H., Remer KA., Brcic M., Fatzer R., Christen S., Leib S., Jungi TW. Inducible nitric oxide synthase and nitrotyrosine in listeric encephalitis: a cross-species study in ruminants. Vet Pathol. 2002; 39: 190-199.
69. Perez LE., Chandrasekar B., et al. Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol. 2006; 176: 5519-5528.
70. Doeing DC., et al. Crockett. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin. Pathol. 2003; 3: 3.
71. Sitnicka E., et al. Jacobsen. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003; 102: 881.
72. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003; 3: 710.
73. Ouellette AJ., et al. Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J. 1996; 10: 1280.
74. Risso A. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukocyte Biol. 2000; 68: 785.
75. Li L, Yan B, Shi YQ, Zhang WQ, Wen ZL. Live imaging reveals differing roles of macrophages and neutrophils during Zebrafish tail fin regeneration. J Biol Chem. 2012; [Epub ahead of print]
76. Cale CM. Cytokines and macrophages: implications for normal and abnormal renal development. Pediatr Nephrol. 1999; 13(8): 709-15.
77. Shrestha A, Horino K, Nishiura H, Yamamoto T. Acquired immune response as a consequence of the macrophage-dependent apoptotic cell clearance and role of the monocyte chemotactic S19 ribosomal protein dimer in this connection. Lab Invest. 1999; 79(12): 1629-42.
78. Barker RN, Erwig L, Pearce WP, Devine A, Rees AJ. Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages. Pathobiology. 1999; 67(5-6): 302-5.
79. Abumaree MH, Chamley LW, Badri M, El-Muzaini MF. Trophoblast debris modulates the expression of immune proteins in macrophages: a key to maternal tolerance of the fetal allograft? J Reprod Immunol. 2012; 94(2): 131-41.
80. Ting Gui, Aiko Shimokado,, Yujing Sun, Takashi Akasaka, Yasuteru Muragaki. Diverse Roles of Macrophages in Atherosclerosis: From Inflammatory Biology to Biomarker discovery. Mediators Inflamm. 2012; doi: 10.1155/2012/693083.
81. Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, et al. Hypoxia Induces EMT in Low and Highly Aggressive Pancreatic Tumor Cells but Only Cells with Cancer Stem Cell Characteristics Acquire Pronounced Migratory Potential. PLoS One. 2012; 7(9): e46391.
82. Waterman RS, Henkle SL, Betancourt AM. Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis. PLoS One. 2012; 7(9): e45590.
83. Siu MK, Wong ES, Kong DS, Chan HY, Jiang L, Wong OG,et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene. 2012; doi: 10.1038/onc.2012.363.
84. Zhou C, Liu J, Tang Y, Liang X. Inflammation linking EMT and cancer stem cells. Oral Oncol. 2012; [Epub ahead of print].
85. Hung SP, Yang MH, Tseng KF, Lee OK. Hypoxia-induced Secretion of TGF-beta 1 in Mesenchymal Stem Cell Promotes Breast Cancer Cell Progression. Cell Transplant. 2012; [Epub ahead of print]
86. DeNarddo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008; 27(1): 11-18.
87. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010 Jun; 29(2): 309-16.
88. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010; 70(19): 7465-75.
89. Erez N, Coussens LM. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer. 2011 Jun 1; 128(11): 2536-44. doi: 10.1002/ijc.26032. Epub 2011 Mar 25.
90. Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011; doi: 10.1101/cshperspect.a003285.
91. Aichel O. About cell fusion with quantitatively abnormal chromosome distribution as cause for tumor formation. In: Rowx W, ed. Vortrageund Aufsatze Uber Entvicklungsmechanik der Organismen. Leipzig, Germany: Wilhelm Engelmann. 1911: 92-111.
92. Pawelek JM, Chakraborty AK. The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res. 2008; 101: 397-444
93. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol. 2005 Dec; 6(12):988-93.
94. Pawelek JM. Viewing malignant melanoma cells as macrophage-tumor hybrids. Cell Adh Migr. 2007; 1(1): 2-6.
95. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow- derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008 May; 8(5): 377-86.
96. Pawelek JM. Cancer-cell fusion with migratory bone-marrow-derived cells as an explanation for metastasis: new therapeutic paradigms. Future Oncol. 2008 Aug; 4(4): 449-52.
97. Lazova R, Chakraborty A, Pawelek JM. Leukocyte-cancer cell fusion: initiator of the warburg effect in malignancy? Adv Exp Med Biol. 2011; 714: 151-72.
98. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-9.
99. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011; 475: 226-30. doi: 10.1038/nature10169. [Pub-94 Med] [Cross Ref.]
100. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353: 2654-66.
101. Zhang L, Conejo-26Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348: 203-13.
102. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-2stage tumors. J Exp Med. 2005; 201: 779-91.
103. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010; 10: 849-59.
104. Singh A, Dey AB, Mohan A, Sharma PK, Mitra DK. Foxp3(+) Regulatory T Cells among Tuberculosis Patients: Impact on Prognosis and Restoration of Antigen Specific IFN-7? Producing T Cells. PLoS One. 2012; 7(9): e44728.
105. Jewett A, Tseng HC, Arasteh A, Saadat S, Christensen RE, Cacalano NA. Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv. 2012 Jan; 9(1): 5-16.
106. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008; 8: 10.
107. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, et al. Safety analysis of exvivo-expanded NK and NK-like cells administered to cancer patients: a phase 1 clinical study. immunotherapy. 2009 Sep; 1(5): 753-64.
108. Szkaradkiewicz A, Karpinski TM, Drews M, Borejsza-Wysocki M, Majewski P, et al. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with cancer. J Biomed Biotechnol. 2010; : 901564.
109. Shen Y, Lu C, Tian W, Wang L, Cui B, Jiao Y, et al. Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol. 2012;40(4): 1285-90.
110. Jewett A, Cacalano NA, Head C, Teruel A. Co-engagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin Cancer Res. 2006; 12(7 Pt 1): 1994-2003.
111. Jewett A, Teruel A, Romero M, Head C, Cacalano N. Rapid and potent induction of cell Death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody. Cancer Immunol Immunother. 2008; 57(7): 1053-66.
112. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive iimmunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother. 2011; 60(11):1565-75.
113. Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y, et al. 2011. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol. 2011 Jan;138(1):23-32.
114. Wu X, Shao Y, Tao Y, Ai G, Wei R, Meng X, et al. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem Biophys Res Commun. 2011 Nov 11; 415(1): 187-92.
115. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One. 2010 Jul 16; 5(7): e11590.
116. Jewett A, Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer. 2011; 2: 443-57.
117. Jewett A, Tseng HC, Arasteh A, Saadat S, Christensen RE, Cacalano NA. Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv. 2012 Jan; 9(1): 5-16.
118. Jewett A, Tseng HC. Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte- induced split anergy in natural killer cells. Cancer Immunol Immunother. 2012 Feb; 61(2): 265-74.
119. Yousefi M, Mattu R, Gao C, Man YG. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: Implications for tumor progression and invasion. AIMM , 2005; 13: 30-37.
120. Man YG, Shen T, Zhao YG, Sang QX. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev 2005; 29: 161-169.
121. Man YG. Focal degeneration of aged or injured myoepithelial cells and the resultant auto- immunoreactions are trigger factors for breast tumor invasion. Medical Hypotheses 2007; 69: 1340- 1357.
122. Man YG, Gardner WA. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Med Hypoth 2008; 70: 387-408
123. Hsiao YH, Deng CX, Mason JT, Chou MC, Man YG. Hidden malignant cells within leukocyte aggregates in normal or hyperplastic tissues of pregnancy-associated breast cancer. Cancer Epidemiol. 2011; [Epub ahead of print].
124. Liu AJ, Wei LX, Gardner WA, Man YG. Correlated alterations in prostate basal cell layer and basement membrane. Int J Biol Sci. 2009; 5: 276-285.
125. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Bratthauer GL,Wheeler DT, Liang CL, Vinh TN, Strauss BL. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res. 2003; 5: 231-241.
126. Man YG, Zhang Y, Shen T, Vinh TN, Zeng X, Tauler J, Mulshine JL, Strauss BL. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat. 2005; 89: 199-208.
127. Man YG, Zhao CQ, Wang J. Breast tumor cell clusters and their budding derivatives show different immunohistochemical profiles during stromal invasion: implications for hormonal and drug therapies. Cancer Therapy. 2006; 4: 193-204.
128. Zhang XC, Hashemi SS, Yousefi M, Gao CL, Sheng J, Mason J, Man YG. Atypical expression of c-erbB2 in cell clusters overlying focally disrupted breast myoepithelial cell layers: a potential sign for increasing cell motility and invasion. Int J Biol Sci. 2008; 4: 259-269.
129. Man YG. Tumor cell budding from focally disrupted tumor capsules: a common pathway for all breast cancer subtype derived invasion? Journal of Cancer 2010; 1: 27-31.
130. Man YG. A seemingly most effective target for early detection and intervention of prostate tumor invasion. J Cancer. 2010; 1: 63-69.
131. Song GH, Ren J, Stojadinovic A, Yong HY, Chen W, Liu ML, Grinkemeyer M, Man YG. Differential impact of lymphocyte infiltration on basal and luminal cells: Implications for breast and prostate tumor invasion and metastasis. Submitted.
132. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994; 24: 114-8.
133. Bounkhoff H. Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. Eur Urol. 1996; 30: 201-5.
134. Botticelli AR. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate. Pathologica 1994; 86: 128-41.
135. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 526-29.
136. Sheng S, Pemberton PA, Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994; 269:30988-93.
137. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25:1954-60.
138. Sternlight MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997; 48:37-46.
139. Brummer T, Schramek D, Hayes VM, Bennett HL, Callon CE, Musgrove EA, Daly RJ. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 2006; 281:626-31.
140. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005; 124(Suppl):S16-28.
141. Yanochko GM, Eckhart W. Type 1 insulin-like growth factor overexpression induce proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 2006; 8(2): R18-R23.
142. Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res. 1994; 14: 2465-72.
143. Boulikas T. Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Expr 1995; 5: 1-77.
144. Chakravarthy MV, Spangenhurg EE, Booth FW. Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell Mol Life Sci 2001; 58:1150-58.
145. Csete M, Walikonis J, Slawny N, et al. Oxygen-mediated regulation of skeletal muscle satellite cell proliferation and adipogrnesis in culture. J Cell Physical 2001; 189:189-96.
146. Studer L, Csete M, Lee SH. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowed pxygen. J Neurosci. 2000; 20: 7377-83.
147. Asano-kato N, Fukagawa K, Okada N. Tryptase increase proliferative activity of human conjunctive fibroblasts through protease-activated receptor. Invest Ophthalmol Vis Sci 2005; 46:4622-6.
148. Freeman MR, Schneck FX, Gognon ML, Corless C, Soker S, Niknejad K, et al. Peripheral blood T- lymphocytes and lymphocytes infiltrating human cancers express vascular endothelianl growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-5.
149. Nienartowicz A, Sobaniee-Lotowska ME, et al. Mast cells in neoangiogenesis. Med Sci Monit 2006; 12(3): 53-6.
150. Qu Z. Immunohistological detection of growth factors and cytokines in tissue mast cells. Methods Mol Biol , 2006; 315: 257-72.
151. Takahashi Y, Bucana CD, Liu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-51.
152. Kang Y, Massague J. Epithelial-mesenchymal transition: twist in development and metastasis. Cell 2004; 118: 277-9.
153. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 2004; 92: 47-56.
154. Strizzi L, Bianco C, Normanno N. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Criptol-1 transgenic mice. J Cell Physiol 2004; 201:266-76.
155. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer. 2006 Apr; 6(4): 281-91.
156. Hu M and Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008; 18(1): 27-34.
157. Puspa Raj Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Front Biosci 2011; 15: 226-236.
158. Man YG, Harley R, Mason J, Gardner WA. Contributions of leukocytes to tumor invasion and metastasis: the "piggy-back" hypothesis. Cancer Epidem 2010; 34: 3-6.
159. Man YG, Mason J, Harley R, Kim YH, Zhu KM, Gardner WA. Leukocyte- facilitated tumor dissemination: a novel model for tumor cell dissociation and metastasis. J Cell Biochem . 2011; 112: 1154-1167.
160. Man YG. Aberrant leukocyte infiltration: a direct trigger for breast tumor invasion and metastasis. Int J Biol Sci 2010; 6(2): 129-132.
161. Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, Trapani JA. Cytotoxic lymphocytes; instigators of dramatic target cell death. Biochem Pharmacol 2004; 68(6):1033-40.
162. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010; 17(4): 616-623.
163. Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. 2009; 128(1): 7-15.
164. de Saint Basile G, Ménasché G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010; 10(8):568-579.
165. Alga AM, Rothwell PM. Effects of regular asprin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; Epub ahead of print.